Investor Presentation First Nine Months of 2023
11
Investor presentation
First nine months of 2023
Generating evidence with the semaglutide molecule beyond
glycaemic control and weight loss
Serious chronic diseases are associated with
Millions of patients are affected globally
ILLUSTRATIVE
PAD
AD
diabetes and obesity
MASH
Diabetes
537 million¹
Obesity
>764 million²
CKD
G₁₂O
CVD
HF
G₁
CKD: 700 million³
ت
|
Novo NordiskⓇ
Novo Nordisk is generating evidence to adress
the medical unmet need in subpopulations
FLOW
I
MASH: ~25 million4
I
ESSENCE
|
CVD: ~520 million 5
SELECT
SOUL
HF: ~64 million 6
STEP
HFPEF
STEP
HFPEF-DM
PAD: ~200 million?
STRIDE
T
I
Alzheimer's Disease: ~85 million8
evoke
evoke+
1International Diabetes Federation: Diabetes Atlas 10th edition, 2021; 2World Diabetes Atlas 2022; ³Carney EF. Nat Rev Nephrol 2020;16:251; 4Estes C et al. Hepatology, 2018; 5Roth GA et al. J Am Coll Cardiol 2020; 6Groenewegen A et al. Eur J Heart Fail
2020;22:1342-13561; Fowkes FG et al. Lancet 2013; 8WHO, Dementia key facts 2022
ASCVD: Atherosclerotic cardiovascular disease; MASH: Metabolic dysfunction-associated steatohepatitis; CVOT: Cardiovascular outcome trial; T2D: Type 2 diabetes; CKD: Chronic kidney disease; PAD: Peripheral arterial disease; HF: Heart failure; HFpEF: Heart
failure with preserved ejection fraction, HFPEF-DM; Heart failure with preserved ejection fraction with Diabetes; s.c.: Subcutaneous.View entire presentation